Studies of spironolactone in people
7 studies gave spironolactone to people and measured what changed
| What changed | Design | People | Source |
|---|---|---|---|
up: Increases time in target systolic blood pressure range3% (95% CI −1 to 7%) | Review of trialsfirst year | 18,823 people pooledBothmean age 72±9 yearsOlder adults; Heart failure with LVEF ≥45%; target systolic blood pressure 110–<130 mmHg | ESC Congress 2026 abstract, Oct 26, 2026 |
up: Increases discontinuation due to hyperkalemia | Randomized trial72 weeks | 168 peopleelderlyOlder adults; on irbesartan background therapy | The American journal of the medical sciences, May 20, 2026 |
no change: Has no effect on health status | Randomized trial9 months | 527 peopleBothmedian 73 yearsOlder adults; Patient cohorts | Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, Mar 21, 2026 |
down: Decreases PICP | Randomized trial9 months | 488 peopleIn patients at risk of heart failure | MedComm, Feb 17, 2026 |
down: Lowers the risk of mortality10.0 vs. 7.3%, HR 0.68, 95% CI 0.48–0.96 | Treated cohortabout 3.3 years | 1,619 people898 (55.5%) were women, and 721 (44.5%) were men≥70 yearsElderly heart failure patients with preserved ejection fraction | Frontiers in cardiovascular medicine, Oct 4, 2021 |
down: Lowers the risk of mortalityHR 0.68, 95% CI 0.48-0.96 | Treated cohort | 898 peopleWomen≥70 yearsOlder adults; elderly patients with HFpEF (TOPCAT); no significant sex-treatment interaction (p interaction=0.190) | Research Square, Feb 23, 2021 |
no change: Has no effect on peak VO2adjusted mean difference -0.4 mL/kg per minute; 95% CI -1.1-0.4; P = .38 down: Decreases blood pressure no change: Has no effect on arterial stiffness | Randomized trial9 months | 71 peopleBoth71 ± 1Older adults; older adults with stable compensated HFpEF | Journal of the American Geriatrics Society, May 19, 2017 |